“Think about this as a disruptive technology,” said Tim Ravenscroft, Lentigen’s CEO. “We’re not looking here at incremental improvements for patients. We’re looking at disease cures and really transforming a lot of these diseases for patients. This is not like a slight improvement on an existing therapy. We’re trying to really transform the way patients are managed.” Read more.
Lentigen Receives U.S. Orphan Drug Designation For Novel Gene Therapy For Glioblastoma Multiforme [pdf]